[1]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889-892.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
　HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(7):889-892.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
点击复制

乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年7期
页码:
889-892
栏目:
临床病理
出版日期:
2020-07-05

文章信息/Info

Title:
Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy
作者:
韩丕华1; 袁 权2△
1.陕西省肿瘤医院乳腺二科(西安 710061); 2.陕西省肿瘤医院超声诊断科(西安 710061)
Author(s):
HAN Pihua; YUAN Quan.
Department 2 of Breast Cancer,Shaanxi Provincial Cancer Hospital(Xi'an 710061)
关键词:
乳腺癌;  新辅助化疗;  完全缓解;  病理学;  白细胞介素-22
Keywords:
Breast cancer;  Neoadjuvant chemotherapy;  Complete remission;  Pathology;  Interleukin-22
分类号:
R737.4
DOI:
DOI:10.3969/j.issn.10007377.2020.07.033
文献标志码:
A
摘要:
目的:探究乳腺癌患者血清白细胞介素-22(IL-22)表达水平在新辅助化疗后病理学完全缓解(NAC)中的预测价值。方法:收集接受NAC的女性乳腺癌309例临床资料。依据患者化疗后手术病理结果分为病理学完全缓解(pCR)者和非pCR者。比较两种病理结果患者化疗前血清IL-22水平差异; 通过纳入者工作曲线(ROC)评估血清IL-22诊断pCR的效能; 建立Logistics回归模型以分析血清IL-22表达水平预测NAC后pCR的独立因素。结果:pCR者化疗前血清IL-22水平明显低于非pCR(P<0.01)。ROC曲线显示血清IL-22诊断pCR的AUC为0.910(95%CI 0.876～0.944),灵敏度0.758%,特异度0.943%。单因素分析显示,NAC后pCR与Her-2、孕激素受体PR和血清IL-12表达状态显著相关(P<0.05); 多因素Logistics分析显示,化疗前血清IL-22是NAC后pCR的预测因素(OR=3.494,95%CI:1.257～12.326,P<0.05)。结论:血清IL-22表达状态与NAC效果具有一定相关性,机体低水平IL-22表达有助于对NAC后pCR的预测。
Abstract:
Objective:To investigate the predictive value of serum IL-22 expression level in breast cancer patients for pathological complete resmission after neoadjuvant chemotherapy(NAC). Methods:The clinical data of 309 women with breast cancer who received NAC were collected. Patients were divided into pathological complete remission(pCR)and non-pCR based on the surgical pathological results after chemotherapy. The serum IL-22 level between the two pathological results before chemotherapy was compared. The efficacy of serum IL-22 in diagnosing pCR was assessed by ROC. The Logistic regression model was established to analyze the independent factors of serum IL-22 expression level in predicting PCR after NAC. Results:The level of serum IL-22 in pCR patients before chemotherapy were significantly lower than that in non-pCR patients(P<0.01). The ROC curve showed that the AUC of serum IL-22 in the diagnosis of pCR was 0.910(95%CI 0.876-0.944),the sensitivity was 0.758,and the specificity was 0.943. Univariate analysis showed that pCR was significantly correlated with the expression of Her-2,PR and serum IL-22 after NAC(P<0.05). Multivariate Logistic analysis showed that serum IL-22 before chemotherapy was a predictor of pCR after NAC(OR=3.494,95%CI 1.257-12.326,P<0.05). Conclusion:There is a certain correlation between the expression of IL-22 in serum and the effect of NAC. Low-level expression of IL-22 in the body is helpful for predicting pCR after NAC.

参考文献/References:

[1] 杜建姝,王嘉艺,王学梅,等. 乳腺癌主要危险因素的流行趋势与一级预防[J]. 中国初级卫生保健,2019,33(7):43-45.
[2] 韩丕华,宋张骏,杨晓民,等. 乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究[J]. 陕西医学杂志,2019,48(7):842-845.
[3] 焦 武. Neo-Bioscore评分在乳腺癌新辅助化疗预后评估中的价值[J]. 肿瘤学杂志,2019,25(5):432-435.
[4] 高国璇,张 岩,张 虹,等. 乳腺癌新辅助治疗病理完全缓解影响因素及预后分析[J]. 中国实用外科杂志,2016,36(11):1205-1210.
[5] 刘 伟,李健斌,王 涛,等. 乳腺癌分子亚型与新辅助化疗疗效及预后的相关性分析[J]. 中华医学杂志,2016,96(36):2898-2902.
[6] 张 黎,姜 姗,刘 淼,等. IL-38、IL-22和IL-17与乳腺癌发展的相关性研究[J]. 现代免疫学,2018,38(3):237-242.
[7] “乳腺癌 HER-2 检测指南”编写组. 乳腺癌 HER-2 检测指南[J]. 中华病理学杂志,2006,35(10):631-633.
[8] 桑 蝶,王佳玉,袁 芃,等. Ki-67与乳腺癌临床病理特征及新辅助化疗疗效的相关性[J]. 癌症进展,2015,13(3):291-297.
[9] 刘杰娜,张建国,郭宝良,等. 乳腺癌患者Ki-67表达水平对新辅助化疗后病理学完全缓解的预测价值[J]. 中国普通外科杂志,2018,27(5):608-614.
[10] 尹树山,陶 艳,张红英. 雌、孕激素受体在晚期局部乳腺癌中的表达及与患者预后相关性研究[J]. 陕西医学杂志,2019,48(12):1718-1721.
[11] Xuan X,Zhou J,Tian Z,et al. ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling[J]. Clinical and Translational Oncology,2019,1(22):1-13.
[12] Bi Y,Cao J,Jin S,et al. Interleukin-22 promotes lung cancer cell proliferation and migration via the IL-22R1/STAT3 and IL-22R1/AKT signaling pathways[J]. Molecular and Cellular Biochemistry,2016,415(1-2):1-11.
[13] 郭宗强,柳晓义,姜丹丹,等. 白细胞介素-22及白细胞介素-22结合蛋白表达与乳腺癌发生发展的关系[J]. 中华实验外科杂志,2016,33(4):922-925.
[14] Kim K,Kim G,Kim JY,et al. Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation[J]. Carcinogenesis,2014,35(6):1352-1361.
[15] Rui J,Chunming Z,Binbin G,et al. IL-22 promotes the progression of breast cancer through regulating HOXB-AS5[J]. Oncotarget,2017,8(61):103601-103612.
[16] 王晓天,张 辉,宋永胜. 血清 IL-22在肾透明细胞癌患者预后分析中的应用价值[J]. 现代肿瘤医学,2016,24(21):3429-3432.
[17] Guillon A,Gueugnon F,Mavridis K,et al. Interleukin-22 receptor is overexpressed in nonsmall cell lung cancer and portends a poor prognosis[J]. European Respiratory Journal,2016,47(4):1277-1280.

相似文献/References:

[1]乔亚舜,吴瑛琦.乳腔镜腋窝淋巴结清扫术治疗早期乳腺癌临床研究[J].陕西医学杂志,2019,(4):473.
　QIAO Yashun,WU Yingqi..Clinical study of mammoscopic axillary lymph node dissection for early breast cancer patients[J].,2019,(7):473.
[2]谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,(5):617.
[3]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
　HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(7):842.
[4]蒋 敢,王 军,王会东△.舒芬太尼联合罗哌卡因肋间神经阻滞对乳腺癌患者术后镇痛、免疫功能及应激反应的影响*[J].陕西医学杂志,2019,(8):1077.
　JIANG Gan,WANG Jun,WANG Huidong..Effect of sufentanil plus ropivacaine intercostal nerve block on postoperative analgesia, immunity and stress response in patients with breast cancer[J].,2019,(7):1077.
[5]王群拴,黎小花△.核磁共振结合血清肿瘤标志物及细胞因子检测在〖JZ〗乳腺癌诊断中的应用价值研究*[J].陕西医学杂志,2019,(10):1295.
[6]钟 亮,廖荣伟,刘清壮,等.调强适形放疗联合新辅助化疗治疗上下行型鼻咽癌疗效研究*[J].陕西医学杂志,2020,49(8):964.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.013]
　ZHONG Liang,LIAO Rongwei,LIU Qingzhuang,et al.Effect of intensity-modulated radiotherapy combined with neoadjuvant chemotherapy in treatment of ascending and descending types of nasopharyngeal carcinoma[J].,2020,49(7):964.[doi:DOI:10.3969/j.issn.1000-7377.2020.08.013]
[7]韩金怡,苏志勇.21基因检测对早期Luminal A型乳腺癌治疗指导作用研究[J].陕西医学杂志,2021,50(9):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
　HAN Jinyi,SU Zhiyong.Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer[J].,2021,50(7):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
[8]白玲娇,陈小军,王 婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.015]
[9]宋养荣,程 蒿,刘 佳,等.Ⅲ期食管癌新辅助化疗后行腔镜手术治疗临床研究[J].陕西医学杂志,2021,50(11):1358.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.009]
　SONG Yangrong,CHENG Hao,LIU Jia,et al.Clinical efficacy of endoscopic surgery after neoadjuvant chemotherapy for stage Ⅲ esophageal cancer[J].,2021,50(7):1358.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.009]
[10]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
　ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(7):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
[11]王玉龙,张美荣,周 昱.乳腺癌患者血清微小RNA-135b、微小RNA-148a-3p、微小RNA-186-5p表达水平及其与新辅助化疗效果相关性研究[J].陕西医学杂志,2024,(5):684.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.024]
　WANG Yulong,ZHANG Meirong,ZHOU Yu.Levels of serum miR-135b,miR-148a-3p and miR-186-5p in breast cancer patients and their correlation with the effect of neoadjuvant chemotherapy[J].,2024,(7):684.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.024]
[12]周永安,阮 勇.白蛋白结合型紫杉醇与多西紫杉醇在人表皮生长因子受体-2阳性乳腺癌患者新辅助化疗中的疗效对比研究[J].陕西医学杂志,2024,(9):1236.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.018]
　ZHOU Yongan,RUAN Yong.Efficacy of albumin-bound paclitaxel and docetaxel in neoadjuvant chemotherapy of patients with HER2-positive breast cancer[J].,2024,(7):1236.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.018]

备注/Memo

备注/Memo:
*陕西省自然科学基金资助项目(2014D4)
更新日期/Last Update: 2020-07-28